Statement: Less than 2% of patients in the primary trial experienced an adverse event.
Primary_evidence: Adverse Events 1:   Total: 6/168 (3.57%)   FEBRILE NEUTROPENIA 3/168 (1.79%)   ENTERITIS 1/168 (0.60%)   PERIPHERAL NEUROPATHY 2/168 (1.19%)   DEPRESSION 1/168 (0.60%)